The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Leslie L. Citrome

Department of Psychiatry

New York University School of Medicine

New York

USA

[email]@nki.rfmh.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Psychiatry, New York University School of Medicine, New York, USA. 1999 - 2010
  • Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA. 2009 - 2010
  • Department of Psychiatry, New York University School of Medicine; and the Nathan S. Kline Institute for Psychiatric Research, Orangeburg, USA. 2000 - 2010

References

  1. Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Citrome, L. Int. J. Clin. Pract. (2010) [Pubmed]
  2. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities. Citrome, L., Jaffe, A., Levine, J. Schizophr. Res. (2010) [Pubmed]
  3. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Citrome, L. Expert. Opin. Drug. Metab. Toxicol (2010) [Pubmed]
  4. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome, L. Postgrad. Med (2010) [Pubmed]
  5. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Citrome, L. Expert. Rev. Neurother (2010) [Pubmed]
  6. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Citrome, L. Int. J. Clin. Pract. (2010) [Pubmed]
  7. Relative vs. absolute measures of benefit and risk: what's the difference?. Citrome, L. Acta. Psychiatr. Scand (2010) [Pubmed]
  8. Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009. Citrome, L., Jaffe, A., Levine, J. Psychiatr. Serv (2010) [Pubmed]
  9. How to efficiently maintain your own electronic resource library. Citrome, L., Moss, S.V. J. Clin. Psychiatry (2010) [Pubmed]
  10. Citability of original research and reviews in journals and their sponsored supplements. Citrome, L. PLoS. ONE (2010) [Pubmed]
  11. Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction? Citrome, L., Kantrowitz, J.T. Expert. Rev. Neurother (2009) [Pubmed]
  12. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Citrome, L. Int. J. Clin. Pract. (2009) [Pubmed]
  13. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? Citrome, L. J. Clin. Psychiatry (2009) [Pubmed]
  14. Using oral ziprasidone effectively: the food effect and dose-response. Citrome, L. Adv. Ther (2009) [Pubmed]
  15. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Citrome, L. Int. J. Clin. Pract. (2009) [Pubmed]
  16. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Citrome, L., Reist, C., Palmer, L., Montejano, L., Lenhart, G., Cuffel, B., Harnett, J., Sanders, K.N. Schizophr. Res. (2009) [Pubmed]
  17. Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Citrome, L., Yang, R., Glue, P., Karayal, O.N. Schizophr. Res. (2009) [Pubmed]
  18. Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder. Citrome, L., Reist, C., Palmer, L., Montejano, L.B., Lenhart, G., Cuffel, B., Harnett, J., Sanders, K.N. Schizophr. Res. (2009) [Pubmed]
  19. How dosing of ziprasidone in a state hospital system differs from product labeling. Citrome, L., Jaffe, A., Levine, J. J. Clin. Psychiatry (2009) [Pubmed]
  20. How to search and harvest the medical literature: let the citations come to you, and how to proceed when they do. Citrome, L., Moss, S.V., Graf, C. Int. J. Clin. Pract. (2009) [Pubmed]
  21. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Citrome, L. Expert. Rev. Neurother (2009) [Pubmed]
  22. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Citrome, L. Int. J. Clin. Pract. (2009) [Pubmed]
  23. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Citrome, L. Curr. Drug. Saf (2009) [Pubmed]
  24. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. Citrome, L., Stauffer, V.L., Chen, L., Kinon, B.J., Kurtz, D.L., Jacobson, J.G., Bergstrom, R.F. J. Clin. Psychopharmacol (2009) [Pubmed]
  25. Teaching the philosophy and tools of evidence-based medicine: misunderstandings and solutions. Citrome, L., Ketter, T.A. Int. J. Clin. Pract. (2009) [Pubmed]
  26. Schizophrenia, obesity, and antipsychotic medications: what can we do? Citrome, L., Vreeland, B. Postgrad. Med (2008) [Pubmed]
  27. Public-academic partnerships: integrating state psychiatric hospital treatment and clinical research. Citrome, L., Epstein, H., Nolan, K.A., Trémeau, F., Elin, C., Roy, B., Levine, J. Psychiatr. Serv (2008) [Pubmed]
  28. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Citrome, L. Int. J. Clin. Pract. (2008) [Pubmed]
  29. Did CATIE influence antipsychotic use?. Citrome, L., Jaffe, A., Martello, D., Allingham, B., Levine, J. Psychiatr. Serv (2008) [Pubmed]
  30. Current guidelines and their recommendations for prolactin monitoring in psychosis. Citrome, L. J. Psychopharmacol. (Oxford) (2008) [Pubmed]
  31. Compelling or irrelevant? Using number needed to treat can help decide. Citrome, L. Acta. Psychiatr. Scand (2008) [Pubmed]
  32. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Citrome, L., Kantrowitz, J. Expert. Rev. Neurother (2008) [Pubmed]
  33. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Citrome, L.L., Holt, R.I., Zachry, W.M., Clewell, J.D., Orth, P.A., Karagianis, J.L., Hoffmann, V.P. Ann. Pharmacother (2007) [Pubmed]
  34. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Citrome, L., Shope, C.B., Nolan, K.A., Czobor, P., Volavka, J. Int. Clin. Psychopharmacol (2007) [Pubmed]
  35. The effectiveness criterion: balancing efficacy against the risks of weight gain. Citrome, L. J. Clin. Psychiatry (2007) [Pubmed]
  36. Show me the evidence: using number needed to treat. Citrome, L. South. Med. J. (2007) [Pubmed]
  37. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. Citrome, L. J. Clin. Psychiatry (2007) [Pubmed]
  38. Pharmacokinetics of aripiprazole and concomitant carbamazepine. Citrome, L., Macher, J.P., Salazar, D.E., Mallikaarjun, S., Boulton, D.W. J. Clin. Psychopharmacol (2007) [Pubmed]
  39. Datapoints: The ups and downs of dosing second-generation antipsychotics. Citrome, L., Jaffe, A., Levine, J. Psychiatr. Serv (2007) [Pubmed]
  40. Paliperidone: quo vadis?. Citrome, L. Int. J. Clin. Pract. (2007) [Pubmed]
  41. Atypical antipsychotics, elderly patients, and mortality risk. Citrome, L. South. Med. J. (2007) [Pubmed]
  42. Introduction: weighing the evidence: weight management insights for treating major mental illness. Citrome, L. J. Clin. Psychiatry (2007) [Pubmed]
  43. Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. Citrome, L., Volavka, J., Czobor, P., Brook, S., Loebel, A., Mandel, F.S. J. Clin. Psychiatry (2006) [Pubmed]
  44. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Citrome, L. Neuropsychiatr. Dis. Treat (2006) [Pubmed]
  45. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Citrome, L., Jaffe, A., Levine, J., Martello, D. Psychiatr. Serv (2006) [Pubmed]
  46. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?. Citrome, L., Stroup, T.S. Int. J. Clin. Pract. (2006) [Pubmed]
  47. The many faces of bipolar disorder. How to tell them apart. Citrome, L., Goldberg, J.F. Postgrad. Med (2005) [Pubmed]
  48. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Citrome, L., Goldberg, J.F., Stahl, S.M. Harv. Rev. Psychiatry (2005) [Pubmed]
  49. Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. Citrome, L. Int. J. Neuropsychopharmacol. (2005) [Pubmed]
  50. Metabolic issues in patients with severe mental illness. Citrome, L., Blonde, L., Damatarca, C. South. Med. J. (2005) [Pubmed]
  51. Metabolic syndrome and cardiovascular disease. Citrome, L. J. Psychopharmacol. (Oxford) (2005) [Pubmed]
  52. Do guidelines for severe mental illness promote physical health and well-being?. Citrome, L., Yeomans, D. J. Psychopharmacol. (Oxford) (2005) [Pubmed]
  53. Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies. Citrome, L., Jaffe, A., Levine, J., Lindenmayer, J.P. J. Clin. Psychiatry (2005) [Pubmed]
  54. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Citrome, L., Casey, D.E., Daniel, D.G., Wozniak, P., Kochan, L.D., Tracy, K.A. Psychiatr. Serv (2004) [Pubmed]
  55. A study of the safety, efficacy, and tolerability of switching from the standard delayed release preparation of divalproex sodium to the extended release formulation in patients with schizophrenia. Citrome, L., Tremeau, F., Wynn, P.S., Roy, B., Dinakar, H. J. Clin. Psychopharmacol (2004) [Pubmed]
  56. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Citrome, L.L. Drugs. Today (2004) [Pubmed]
  57. New treatments for agitation. Citrome, L. Psychiatr. Q (2004) [Pubmed]
  58. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Citrome, L., Jaffe, A., Levine, J., Allingham, B., Robinson, J. Psychiatr. Serv (2004) [Pubmed]
  59. The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. Citrome, L., Volavka, J. Postgrad. Med (2004) [Pubmed]
  60. Relationship of atypical antipsychotics with development of diabetes mellitus. Citrome, L.L., Jaffe, A.B. Ann. Pharmacother (2003) [Pubmed]
  61. Schizophrenia and valproate. Citrome, L. Psychopharmacol. Bull (2003) [Pubmed]
  62. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Citrome, L., Volavka, J. Harv. Rev. Psychiatry (2002) [Pubmed]
  63. Use of mood stabilizers among patients with schizophrenia, 1994-2001. Citrome, L., Jaffe, A., Levine, J., Allingham, B. Psychiatr. Serv (2002) [Pubmed]
  64. Atypical antipsychotics for acute agitation. New intramuscular options offer advantages. Citrome, L. Postgrad. Med (2002) [Pubmed]
  65. Atypical antipsychotics: revolutionary or incremental advance?. Citrome, L., Volavka, J. Expert. Rev. Neurother (2002) [Pubmed]
  66. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Citrome, L., Volavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.P., McEvoy, J., Cooper, T.B., Chakos, M., Lieberman, J.A. Psychiatr. Serv (2001) [Pubmed]
  67. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Citrome, L., Levine, J., Allingham, B. Psychiatr. Serv (2000) [Pubmed]
  68. Violent patients in the emergency setting. Citrome, L., Volavka, J. Psychiatr. Clin. North Am. (1999) [Pubmed]
 
WikiGenes - Universities